TY - JOUR T1 - First-in-Human Experience of CXCR4-Directed Endoradiotherapy with <sup>177</sup>Lu- and <sup>90</sup>Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 248 LP - 251 DO - 10.2967/jnumed.115.167361 VL - 57 IS - 2 AU - Ken Herrmann AU - Margret Schottelius AU - Constantin Lapa AU - Theresa Osl AU - Andreas Poschenrieder AU - Heribert Hänscheid AU - Katharina Lückerath AU - Martin Schreder AU - Christina Bluemel AU - Markus Knott AU - Ulrich Keller AU - Andreas Schirbel AU - Samuel Samnick AU - Michael Lassmann AU - Saskia Kropf AU - Andreas K. Buck AU - Hermann Einsele AU - Hans-Juergen Wester AU - Stefan Knop Y1 - 2016/02/01 UR - http://jnm.snmjournals.org/content/57/2/248.abstract N2 - Chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand (68Ga-pentixafor) for diagnostic receptor targeting, 177Lu- and 90Y-pentixather were recently developed as endoradiotherapeutic vectors. Here, we summarize the first-in-human experience in 3 heavily pretreated patients with intramedullary and extensive extramedullary manifestations of multiple myeloma undergoing CXCR4-directed endoradiotherapy. Methods: CXCR4 target expression was demonstrated by baseline 68Ga-pentixafor PET. Each treatment was approved by the clinical ethics committee. Pretherapeutic 177Lu-pentixather dosimetry was performed before 177Lu-pentixather or 90Y-pentixather treatment. Subsequently, patients underwent additional chemotherapy and autologous stem cell transplantation for bone marrow rescue. Results: A remarkable therapeutic effect was visualized in 2 patients, who showed a significant reduction in 18F-FDG uptake. Conclusion: CXCR4-targeted radiotherapy with pentixather appears to be a promising novel treatment option in combination with cytotoxic chemotherapy and autologous stem cell transplantation, especially for patients with advanced multiple myeloma. ER -